title: Colchicine use during breastfeeding.
abstract: OBJECTIVE
  This study evaluated the outcome of infants exposed to colchicine during lactation.
  
  
  METHODS
  A prospective observational cohort study design was used. Mothers who contacted Beilinson Teratology Information Service (BELTIS) regarding use of colchicine while breastfeeding were followed up by phone interview. Data on lactation, neonatal symptoms, and outcome 1-3 years after initial consultation were obtained. Mothers breastfeeding while taking colchicine (n=37) and their infants (n=38) were compared with a matched control group of mothers using a drug known to be safe during lactation (n=75) and their infants (n=76).
  
  
  RESULTS
  Follow-up was obtained for 59 of 76 (78%) women who contacted BELTIS regarding use of colchicine. Of the 59 women, 37 breastfed while taking colchicine, five did not take colchicine, 16 did not breastfeed, and one declined to participate. The mean duration of breastfeeding was similar in both groups. Adverse neonatal symptoms were seen in three of 38 colchicine-exposed infants versus four of 76 of control group infants (p=0.68). Delayed development or neurological abnormalities were seen in two infants in both study groups (p=0.60). None of the colchicine-exposed infants showed abnormal growth.
  
  
  CONCLUSIONS
  No increase in adverse long-term outcomes was found in colchicine-exposed breastfed infants. Our data support continuation of breastfeeding in women treated with colchicine.
authors: 1 Neonatal Intensive Care Unit, Schneider Children's Medical Center of Israel , Petah Tiqva, Israel .
authors: Tina
authors: T
authors: Herscovici
authors: Paul
authors: P
authors: Merlob
authors: Bracha
authors: B
authors: Stahl
authors: Tami
authors: T
authors: Laron-Kenet
authors: Gil
authors: G
authors: Klinger
mesh_terms: D000328:Adult; D001942:Breast Feeding; D003078:Colchicine / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D010505:Familial Mediterranean Fever / Q000188:drug therapy*; D005260:Female; D006074:Gout Suppressants / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007774:Lactation / Q000187:drug effects*; D008895:Milk, Human / Q000737:chemistry / Q000187:drug effects*; D009035:Mothers; D011247:Pregnancy; D011446:Prospective Studies; D018570:Risk Assessment
chemical_list: D006074:Gout Suppressants; D003078:Colchicine